Sanofi Q2 2026: India profit up, guidance raised

Key takeaways at a glance

Sanofi Consumer Healthcare India Limited reported higher revenue and profit for the quarter ended June 30, 2026, backed by domestic growth and improved operating margins. The company’s board also approved the unaudited Q2 and half-year results and submitted them with a limited review report to stock exchanges as required under SEBI Listing Regulations. Separately, parent Sanofi reported strong Q2 2026 performance globally, including double-digit sales growth at constant exchange rates and an upgrade to its 2026 outlook.

What Sanofi Consumer Healthcare India reported for Q2 CY2026

For Q2 2026, Sanofi Consumer Healthcare India reported revenue from operations of ₹2,357 million, a 7% year-on-year increase. Profit before tax rose 16% year-on-year to ₹919 million. Profit for the period came in at ₹688 million, compared with ₹607 million in the same quarter last year.

The company also disclosed earnings per share (EPS) of ₹29.87 for the quarter, up from ₹26.36 a year ago. Alongside the statutory financials, the company attributed domestic demand to product relaunches, including brands such as Combiflam, Allegra, and Depura.

Domestic growth helped offset export weakness

In its earnings summary, the company said domestic sales grew 12% in Q2 2026. Export sales declined 9% during the quarter, with the company citing a high base. This mix matters for investors because the quarter’s growth was largely driven by the home market, while exports were a drag.

For the half-year ended June 30, 2026, management commentary pointed to a stronger export trend, stating export sales rose 27% on a low base, while domestic sales increased 14%.

Margin expansion and operating performance in the quarter

Operating performance improved in Q2 2026, with EBITDA rising 27.2% year-on-year to ₹893 million from ₹702 million. EBITDA margin expanded to 37.9% from 31.8% in the year-ago quarter, reflecting stronger profitability even as revenue growth remained in single digits.

This margin expansion was one of the standout data points in the Q2 disclosures, as it indicates operating leverage and/or cost discipline during the period.

H1 CY2026: faster revenue growth and higher profit

For the six months ended June 30, 2026, Sanofi Consumer Healthcare India reported revenue from operations of ₹4,649 million, up 18% year-on-year. Net income for the half-year was ₹1,366 million, compared with ₹1,107 million in the corresponding period last year.

The company also reported half-year EPS of ₹59.31, up from ₹48.07 a year ago. Profit before tax for the half-year increased 25% year-on-year, based on the earnings summary provided.

Cash position and balance sheet update

Sanofi Consumer Healthcare India reported cash and cash equivalents of ₹4,902 million as of June 30, 2026. This compares with ₹3,748 million as of December 31, 2025. The higher cash balance can be relevant for shareholders tracking liquidity, working capital movements, and capacity for dividends or reinvestment.

Board approvals, audit review, and disclosures

The company said its Board of Directors approved the unaudited financial results for the quarter and half-year ended June 30, 2026 at a meeting held on July 28, 2026. It also submitted the results along with the Limited Review Report from statutory auditors Price Waterhouse & Co Chartered Accountants LLP, in line with SEBI Listing Regulations.

In a separate intimation, the company said the financial results notice was published in Business Standard and Sakal newspapers on July 30, 2026, and the results would also be available on the investor website.

Parent Sanofi’s global Q2 2026: sales up, EPS stronger

Sanofi’s global update for Q2 2026 reported net sales of €11,597 million, up 17.8% at constant exchange rates (CER). Business EPS was €2.09, up 33.3% at CER (31.4% at actual exchange rates), while IFRS EPS was €0.29.

Key product lines also moved sharply. Pharma launches sales increased 48.3% to €1,300 million, driven mostly by Ayvakit, ALTUVIIIO, and Sarclisa. Dupixent sales rose 37.6% to €5,200 million, crossing €5,000 million per quarter for the first time. Vaccines sales fell 4.7% to €1,100 million, impacted by a high comparison base in influenza vaccines.

Costs, cash flow, and what changed in guidance

Sanofi reported R&D expenses of €2,200 million, up 17.9%, including costs linked to pipeline prioritizations. Selling and general expenses reached €2,500 million, up 9.0%, mainly due to recent acquisitions and one-off items.

On cash generation, free cash flow in Q2 2026 was €2,670 million, up 86.8%. Based on the Q2 release, Sanofi also upgraded its 2026 guidance, stating that sales are now expected to grow by around 10% at CER.

Snapshot table: key reported numbers

Why this matters for India-market investors

For Indian investors tracking Sanofi Consumer Healthcare India, the Q2 print combined steady revenue growth with a sharper rise in profitability, supported by a significant improvement in EBITDA margin. The split between domestic and export performance is also important: domestic growth remained the primary driver in Q2, while exports declined on a high base.

At the parent level, Sanofi’s global results underline improving earnings momentum and a clearer growth outlook for 2026, with sales now guided to rise by around 10% at CER. While the India listed entity’s performance is driven by its own product portfolio and market dynamics, parent-level execution and pipeline priorities can influence broader brand strategy, resource allocation, and investor sentiment.

Conclusion

Sanofi Consumer Healthcare India’s Q2 2026 results showed higher revenue, stronger profit growth, and margin expansion, alongside formal board approval and timely disclosures. Globally, Sanofi posted double-digit Q2 sales growth at CER and raised its 2026 sales growth guidance to around 10% at CER. The next concrete checkpoint for investors will be subsequent scheduled disclosures and management commentary as the company progresses through the rest of CY2026.